

해외 바이오의약품 임상 현황 (2021.1.4~2021.1.10)

한국바이오의약품협회, 2021.1.12.  
출처: ClinicalTrials.gov

○ 미국 22건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04441047	Universal Anti-Viral Vaccine for Healthy Elderly Adults	Virus Diseases	Drug: AlloStim	Immunovative Therapies, Ltd; Mirror Biologics, Inc.	Phase 1  Phase 2	
NCT04594811	NT-17 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma	Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)	Drug: NT-17 Drug: Nivolumab	NeolmmuneTech Bristol-Myers Squibb	Phase 2	
NCT04444622	Immunotherapy for Third Line Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	Biological: AlloStim	Immunovative Therapies, Ltd; Mirror Biologics, Inc.	Phase 2	
NCT04442581	Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer	Advanced Hepatocellular Carcinoma BCLC Stage B Hepatocellular Carcinoma BCLC Stage C Hepatocellular Carcinoma	Drug: Cabozantinib S-malate Biological: Pembrolizumab	University of Washington National Cancer Institute (NCI)	Phase 2	
NCT04387227	Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma	Drug: Carboplatin Biological: Pembrolizumab	University of Washington National Cancer Institute (NCI) United States Department of Defense	Phase 2	
NCT04384692	Ruxolitinib for the Treatment of Graft Versus Host Disease Following Stem Cell Transplant in Patients With Primary and Secondary Myelofibrosis	Primary Myelofibrosis Secondary Myelofibrosis	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Busulfan Drug: Cyclophosphamide Drug: Fludarabine Drug: Melphalan Drug: Methotrexate Drug: Mycophenolate Mofetil Drug: Ruxolitinib Drug: Tacrolimus Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2	
NCT04372927	ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy	Locally Advanced Lung Non-Small Cell Carcinoma Stage III Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8 Stage IIIC Lung Cancer AJCC v8	Drug: Cisplatin Biological: Durvalumab Drug: Etoposide Radiation: Hypofractionated Radiation Therapy Drug: Pemetrexed	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 2	
NCT04370301	Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis	Primary Myelofibrosis Secondary Myelofibrosis	Drug: Cyclophosphamide Drug: JAK Inhibitor Drug: Fludarabine Biological: Recombinant Granulocyte Colony-Stimulating Factor Drug: Melphalan Drug: Mycophenolate Mofetil Procedure: Peripheral Blood Stem Cell Transplantation Drug: Tacrolimus Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2	
NCT04359784	Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy	B-Cell Non-Hodgkin Lymphoma	Biological: Anakinra Biological: Axicabtagene Ciloleuce	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) Sobi	Phase 2	
NCT04336943	Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load	Biochemically Recurrent Prostate Carcinoma Prostate Adenocarcinoma	Biological: Durvalumab Drug: Olaparib Other: Quality-of-Life Assessment Other: Questionnaire Administration	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 2	
NCT04329065	Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer	Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8	Biological: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine Drug: Paclitaxel Biological: Trastuzumab Biological: Pertuzumab	University of Washington National Cancer Institute (NCI) United States Department of Defense	Phase 2	
NCT04242264	Phase 2 Shigella Vaccine and Challenge	Immunisation Shigella Infection	Other: Placebo Biological: Shigella sonnei strain 53G Biological: WR5s2	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	
NCT04195633	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies	Acute Leukemia Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Adult Diffuse Large Cell Lymphoma Anaplastic Large Cell Lymphoma Burkitt Lymphoma Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Myelomonocytic Leukemia Hodgkin Lymphoma Lymphoblastic Lymphoma Lymphoplasmacytic Lymphoma Mantle Cell Lymphoma Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Polymorphocytic Leukemia Refractory Chronic Lymphocytic Leukemia Refractory Follicular Lymphoma Refractory Marginal Zone Lymphoma Refractory Small Lymphocytic Lymphoma Hematopoietic and Lymphoid Cell Neoplasm	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Cyclophosphamide Drug: Cyclosporine Biological: Filgrastim Drug: Fludarabine Drug: Mycophenolate Mofetil Drug: Mycophenolate Sodium Radiation: Total-Body Irradiation Drug: Treosulfan	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2	
NCT04551430	Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma	Metastatic Soft-tissue Sarcoma	Drug: Cabozantinib Drug: Nivolumab Drug: Ipilimumab	Washington University School of Medicine Exelixis Bristol-Myers Squibb	Phase 2	
NCT04647916	Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases	Anatomic Stage IV Breast Cancer AJCC v8 Invasive Breast Carcinoma Metastatic HER2 Negative Breast Carcinoma Metastatic Malignant Neoplasm in the Brain Prognostic Stage IV Breast Cancer AJCC v8	Biological: Sacituzumab Govitecan	Southwest Oncology Group National Cancer Institute (NCI) Immunomedics, Inc.	Phase 2	
NCT04655807	A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease	Crohn Disease	Drug: JNJ-64304500 Drug: Placebo Drug: Adalimumab Drug: Ustekinumab	Janssen Research & Development, LLC	Phase 2	
NCT04634552	A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma	Hematological Malignancies	Drug: Talquetamab	Janssen Research & Development, LLC	Phase 2	
NCT04630028	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: Ustekinumab Dose Based on BSA and Body Weight Drug: Matching Placebo	Janssen Research & Development, LLC	Phase 3	
NCT04619420	A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease	Alzheimer Disease Cognitive Dysfunction Dementia	Drug: JNJ-63733657 Drug: Placebo	Janssen Research & Development, LLC	Phase 2	
NCT04390113	Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)	BK Virus Infection Hemorrhagic Cystitis	Biological: Viralym-M Biological: Placebo	AlloVir	Phase 3	
NCT03220022	Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas	AIDS-Related Lymphoma Ann Arbor Stage II Diffuse Large B-Cell Lymphoma Ann Arbor Stage III Diffuse Large B-Cell Lymphoma Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma	Drug: Cyclophosphamide Drug: Doxorubicin Hydrochloride Drug: Etoposide Biological: Filgrastim Drug: Ibrutinib Other: Laboratory Biomarker Analysis Biological: Pegfilgrastim Other: Pharmacological Study Drug: Prednisone Biological: Rituximab Drug: Vincristine Sulfate	National Cancer Institute (NCI)	Phase 1	
NCT04521231	A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients	B Cell Precursor Acute Lymphoblastic Leukemia	Drug: Blinatumomab	Amgen	Phase 1	

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04630028	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: Ustekinumab Dose Based on BSA and Body Weight Drug: Matching Placebo	Janssen Research & Development, LLC	Phase 3	

○ 프랑스 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04619420	A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease	Alzheimer Disease Cognitive Dysfunction Dementia	Drug: JNJ-63733657 Drug: Placebo	Janssen Research & Development, LLC	Phase 2	
NCT04655807	A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease	Crohn Disease	Drug: JNJ-64304500 Drug: Placebo Drug: Adalimumab Drug: Ustekinumab	Janssen Research & Development, LLC	Phase 2	
NCT04634552	A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma	Hematological Malignancies	Drug: Talquetamab	Janssen Research & Development, LLC	Phase 2	
NCT04521231	A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients	B Cell Precursor Acute Lymphoblastic Leukemia	Drug: Blinatumomab	Amgen	Phase 1	

해외 바이오의약품 임상 현황 (2021.1.4~2021.1.10)

한국바이오의약품협회, 2021.1.12.  
출처: ClinicalTrials.gov

○ 독일 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04684654	BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome	Healthy Participants Primary Sjögren's Syndrome	Biological: BMS-986325 Other: Placebo	Bristol-Myers Squibb	Phase 1	---
NCT04681430	Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals	Corona Virus Infection SARS-CoV-2 Infection SARS-CoV-2 PCR Test Positive SARS-CoV-2 Acute Respiratory Disease	Biological: Convalescent plasma Drug: Camostat Mesilate Drug: Placebo for Camostat Mesilate Other: Standard of Care (SoC)	Heinrich-Heine University, Duesseldorf The Federal Ministry of Health, Germany (Bundesministerium für Gesundheit, BMG)	Phase 2	---
NCT04655807	A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease	Crohn Disease	Drug: JNJ-64304500 Drug: Placebo Drug: Adalimumab Drug: Ustekinumab	Janssen Research & Development, LLC	Phase 2	---
NCT04630028	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: Ustekinumab Dose Based on BSA and Body Weight Drug: Matching Placebo	Janssen Research & Development, LLC	Phase 3	---
NCT04634552	A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma	Hematological Malignancies	Drug: Talquetamab	Janssen Research & Development, LLC	Phase 2	---
NCT04521231	A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients	B Cell Precursor Acute Lymphoblastic Leukemia	Drug: Blinatumomab	Amgen	Phase 1	---

○ 중국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04692376	MSC for Treatment of cGVHD After Allo-HSCT	Chronic Graft-versus-host Disease	Biological: Mesenchymal stem cells Drug: Glucocorticoids Drug: cyclosporine	Nanfeng Hospital of Southern Medical University Sun Yat-sen University Xinqiao Hospital, Army Medical University Peking University People's Hospital	Phase 2	---

○ 일본 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04619420	A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease	Alzheimer Disease Cognitive Dysfunction Dementia	Drug: JNJ-63733657 Drug: Placebo	Janssen Research & Development, LLC	Phase 2	---
NCT04630028	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: Ustekinumab Dose Based on BSA and Body Weight Drug: Matching Placebo	Janssen Research & Development, LLC	Phase 3	---
NCT04655807	A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease	Crohn Disease	Drug: JNJ-64304500 Drug: Placebo Drug: Adalimumab Drug: Ustekinumab	Janssen Research & Development, LLC	Phase 2	---